Immune checkpoint inhibitors for multiple myeloma immunotherapy

被引：13
作者：
Liu, Zhaoyun [1 ]
Xu, Xintong [1 ]
Liu, Hui [1 ]
Zhao, Xianghong [1 ]
Yang, Chun [1 ]
Fu, Rong [1 ]
机构：
[1] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin 300052, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Immune checkpoint; CTLA-4; TIGIT; Multiple myeloma; treatment strategy; T-LYMPHOCYTE ATTENUATOR; KIR ANTIBODY IPH2101; PHASE-I TRIAL; PD-1; BLOCKADE; DARATUMUMAB MONOTHERAPY; ANTITUMOR IMMUNITY; B-LYMPHOCYTE; PLASMA-CELLS; EXPRESSION; CANCER;
D O I：
10.1186/s40164-023-00456-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closely associated with immune escape. Immune checkpoint-related therapy has attracted much attention and research in MM. However, the efficacy of those therapies need further improvements. There need more thoughts about the immune checkpoint to translate their use in clinical work. In our review, we aggregated the currently known immune checkpoints and their corresponding ligands, further more we propose various ways of potential translation applying treatment based on immune checkpoints for MM patients.
引用
收藏
页数：20
相关论文
共 168 条
[1]  
Abe Masahiro, 2019, Clin Calcium, V29, P349, DOI 10.20837/4201903349
[2]   Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update [J].
Abramson, Hanley N. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
[3]  
Advani R, 2019, NEW ENGL J MED, V380, P497, DOI 10.1056/NEJMc1816156
[4]   Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy [J].
Alfarra, Helmi ;
Weir, Jackson ;
Grieve, Stacy ;
Reiman, Tony .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[5]   Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises [J].
Alkharabsheh, Omar ;
Trisel, Zachary ;
Badami, Sunil ;
Aljama, Mohammed A. ;
Sidiqi, M. Hasib .
CANCERS, 2022, 14 (01)
[6]   PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].
Alsaab, Hashem O. ;
Sau, Samaresh ;
Alzhrani, Rami ;
Tatiparti, Katyayani ;
Bhise, Ketki ;
Kashaw, Sushil K. ;
Iyer, Arun K. .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[7]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[8]   Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies [J].
Ansell, Stephen M. ;
Maris, Michael B. ;
Lesokhin, Alexander M. ;
Chen, Robert W. ;
Flinn, Ian W. ;
Sawas, Ahmed ;
Minden, Mark D. ;
Villa, Diego ;
Percival, Mary-Elizabeth M. ;
Advani, Anjali S. ;
Foran, James M. ;
Horwitz, Steven M. ;
Mei, Matthew G. ;
Zain, Jasmine ;
Savage, Kerry J. ;
Querfeld, Christiane ;
Akilov, Oleg E. ;
Johnson, Lisa D. S. ;
Catalano, Tina ;
Petrova, Penka S. ;
Uger, Robert A. ;
Sievers, Eric L. ;
Milea, Anca ;
Roberge, Kathleen ;
Shou, Yaping ;
O'Connor, Owen A. .
CLINICAL CANCER RESEARCH, 2021, 27 (08) :2190-2199
[9]   PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation [J].
Armand, Philippe ;
Chen, Yi-Bin ;
Redd, Robert A. ;
Joyce, Robin M. ;
Bsat, Jad ;
Jeter, Erin ;
Merryman, Reid W. ;
Coleman, Kimberly C. ;
Dahi, Parastoo B. ;
Nieto, Yago ;
LaCasce, Ann S. ;
Fisher, David C. ;
Ng, Samuel Y. ;
Odejide, Oreofe O. ;
Freedman, Arnold S. ;
Kim, Austin, I ;
Crombie, Jennifer L. ;
Jacobson, Caron A. ;
Jacobsen, Eric D. ;
Wong, Jeffrey L. ;
Patel, Sanjay S. ;
Ritz, Jerome ;
Rodig, Scott J. ;
Shipp, Margaret A. ;
Herrera, Alex F. .
BLOOD, 2019, 134 (01) :22-29
[10]   TIGIT checkpoint inhibition for myeloma [J].
Asimakopoulos, Fotis .
BLOOD, 2018, 132 (16) :1629-1630
12345678910